We are delighted to announce the appointment of Jeff Martens to the position of Managing Director of the Pangaea Group effective October 1, 2024.

The Ontario government is assessing the role of Preferred Provider Networks (PPNs) in Ontario’s employer-sponsored drug insurance program.

The PMPRB has published a Discussion Guide, the next stage towards their updated Guidelines.

According to a recent Federal Court ruling, PMPRB’s jurisdiction over patented drug prices could also apply to an off-patent drug.

The federal government formally announced the creation of the Canadian Drug Agency (CDA), originally identified in the 2019 budget.

The PMPRB has posted its Scoping Paper that poses questions to stakeholders to start the first phase of consultations on its new Guidelines.

The pCPA Board of Directors recently announced Douglas Clark to be the first CEO of the newly incorporated organization, effective Sept 11.

Last week we hosted an incredible session with Canadian Industry Heads! It was great seeing many familiar faces as well as meeting new colleagues. Thank you to everyone that attended, for sharing your perspectives and insights, and contributing to the day’s success.

Health Canada has released its updated Guidance on the Distinction Between Advertising and Other Activities.

In the period between the coming into force of the new Patented Medicines Regulations and the final publication of a corresponding set of guidelines (“Interim Period”), the PMPRB is proposing to adopt a “status quo” approach to carrying out its regulatory mandate.